MPL Mutation Test: Myeloproliferative Neoplasm, Platelets, and Results

An MPL mutation test looks for acquired changes in the MPL gene, most often in people with persistent high platelet counts or other findings that suggest a myeloproliferative neoplasm (MPN). MPL makes the thrombopoietin receptor, a protein that helps regulate platelet-producing cells in bone marrow. Certain mutations, especially at codon W515 in exon 10, can keep growth signaling switched on and support a diagnosis of essential thrombocythemia or primary myelofibrosis. The test is usually performed on blood or bone marrow as part of a panel that also includes JAK2 and CALR. A positive result supports a clonal blood disorder, but it does not establish the exact MPN by itself. Doctors interpret it with blood counts, bone marrow appearance, symptoms, spleen size, and other genetic findings. A negative result also does not rule out an MPN, because some cases have other driver mutations or remain “triple negative.”

• A positive MPL driver mutation supports a clonal MPN, most commonly essential thrombocythemia or primary myelofibrosis.
• MPL W515L and W515K are the best-known pathogenic variants, but laboratories may detect additional activating variants.
• The platelet count and the MPL variant allele fraction measure different things; neither number should be interpreted alone.
• A negative MPL result does not exclude an MPN, especially when JAK2 and CALR testing is also negative.
• No fasting is required for a blood test, although a bone marrow procedure needs separate preparation instructions.

Table of Contents

• What the MPL Test Detects
• When the Test Is Ordered
• How Testing Is Performed
• Positive, Negative, and Uncertain Results
• MPL in Essential Thrombocythemia and Myelofibrosis
• Treatment and Prognosis
• Limitations and Follow-Up
• Questions to Ask

What the MPL Test Detects

The MPL mutation test detects sequence changes in the gene that encodes the thrombopoietin receptor, also called CD110. Thrombopoietin binds this receptor on hematopoietic stem cells and megakaryocytes, the bone marrow cells that make platelets. Normal binding activates JAK-STAT and related signaling pathways for a limited time. Activating MPL mutations allow signaling to continue without the usual control, giving the abnormal clone a growth advantage.

Most clinically relevant acquired MPL mutations in classic MPNs occur in exon 10 around amino acid 515. Reports may list variants in protein notation, such as MPL p.W515L, p.W515K, or p.W515A, and may also provide a DNA-level description. Less common pathogenic variants include changes near S505 and other residues. The report should classify the variant and state whether it is recognized as an MPN driver.

MPL testing in this setting is a somatic test. It examines blood-forming cells for a mutation acquired during life; it is not primarily a test of inherited cancer risk. Rare inherited MPL variants can cause familial thrombocytosis, but that is a different clinical question. A mutation present at a roughly stable level across non-blood tissues, an unusual family history, or childhood-onset thrombocytosis may prompt germline evaluation. That evaluation should use an appropriate nonhematologic specimen and genetic counseling rather than assuming a routine blood result is inherited.

MPL is one of three main driver genes in Philadelphia chromosome-negative classic MPNs. The other two are JAK2 and CALR. These driver mutations are generally mutually exclusive, although rare co-occurrences occur. An JAK2 mutation test is usually performed first or as part of a panel, and a CALR mutation test is important when JAK2 is negative. The driver result helps establish clonality, while morphology and clinical findings define the disease.

The test does not directly measure how well platelets work, predict a specific platelet count, or diagnose every cause of thrombocytosis. It also does not replace testing for BCR::ABL1 when chronic myeloid leukemia is a consideration. Each test answers a different biological question.

When the Test Is Ordered

Clinicians most often order MPL testing after repeated complete blood counts show unexplained thrombocytosis, usually a platelet count of at least 450 × 10⁹/L, or when marrow findings suggest an MPN. A single high count during infection, surgery, blood loss, iron deficiency, or inflammation may be reactive. Persistence, a very high count, abnormal white or red cells, splenomegaly, thrombosis, microvascular symptoms, or characteristic marrow morphology raises concern for a clonal process.

Common reasons for testing include:

• persistent thrombocytosis after common reactive causes have been assessed;
• suspected essential thrombocythemia (ET);
• suspected prefibrotic or overt primary myelofibrosis (PMF);
• unexplained marrow megakaryocyte proliferation or fibrosis;
• an unusual blood clot, especially in a splanchnic vein, with other MPN clues;
• confirmation of a suspected clonal myeloid disorder after negative JAK2 testing;
• broader molecular profiling for prognosis in an established MPN.

The order of testing varies by laboratory. Some use a reflex pathway: JAK2 V617F first, then CALR and MPL if JAK2 is not detected. Others use a single myeloid next-generation sequencing panel. A panel can identify additional mutations in genes such as ASXL1, SRSF2, U2AF1, EZH2, IDH1, IDH2, TET2, and DNMT3A. Those additional findings may help with classification or prognostic scoring, particularly in myelofibrosis, but they do not substitute for a driver-gene assessment.

MPL testing may also be considered when platelet counts are normal or low if marrow fibrosis, leukoerythroblastosis, anemia, constitutional symptoms, or splenomegaly suggest myelofibrosis. Advanced PMF does not always produce high platelets. Conversely, a person with isolated mild thrombocytosis and a clear reversible cause may not need immediate molecular testing.

The test is not a population screening test. It should be ordered because the pretest probability of an MPN is meaningful and because the result can clarify diagnosis or management. A hematologist often coordinates testing when abnormalities persist.

How Testing Is Performed

Most MPL mutation testing uses a peripheral blood sample. Bone marrow aspirate can also be tested, especially when it is already being collected for diagnosis. No fasting is needed for the blood draw. The laboratory extracts DNA and applies a targeted assay or a broader sequencing method.

Method	What it commonly detects	Main advantage	Main limitation
Allele-specific PCR	Selected common variants such as W515L/K	Fast and sensitive	May miss uncommon MPL variants
Targeted sequencing	Exon 10 or a defined MPL region	Broader variant coverage	Coverage and sensitivity vary
Myeloid NGS panel	MPL plus other MPN and myeloid genes	Provides a wider molecular profile	May produce complex or incidental findings
Digital PCR	A known MPL variant at low level	Highly sensitive quantification	Usually requires a predetermined target

A result may include a variant allele fraction (VAF), the percentage of sequence reads carrying the mutation. A VAF of 20%, for example, does not mean 20% of platelets are abnormal or that a person has a 20% cancer risk. The relationship between VAF and the fraction of affected blood cells depends on cell mixture, copy number, zygosity, sample type, and assay design. VAF can be useful as one piece of the molecular profile, but it is not a stand-alone measure of disease burden.

The report should describe the specimen, method, regions covered, detection limit, variant, classification, and VAF when available. It may state “not detected” rather than “negative” because every assay has a lower detection limit and defined coverage. A test limited to W515L/K cannot exclude another pathogenic MPL alteration.

Bone marrow biopsy remains central when ET or PMF is suspected. Pathologists assess megakaryocyte number, size, clustering, nuclear features, overall cellularity, granulocyte and red-cell growth, blast percentage, reticulin or collagen fibrosis, and competing diagnoses. Molecular testing and marrow morphology work together; neither should be treated as a complete diagnosis in isolation.

Positive, Negative, and Uncertain Results

A positive pathogenic MPL result supports a clonal myeloid neoplasm when it fits the clinical setting. In someone with persistent thrombocytosis and ET-like marrow morphology, it may fulfill the molecular component of diagnostic criteria. In someone with marrow fibrosis and typical features, it may support PMF. The same mutation cannot, by itself, distinguish ET from prefibrotic PMF or overt PMF.

A positive result should be read with the exact variant. A recognized activating exon 10 driver has a different meaning from a variant of uncertain significance (VUS). Laboratories classify variants using available clinical, functional, and population evidence. A VUS should not be treated as proof of an MPN and generally should not drive treatment by itself.

A not-detected result can mean several things:

• no MPL mutation is present;
• the disease is driven by JAK2, CALR, or another mutation;
• the MPL variant lies outside the assay’s tested region;
• the abnormal clone is below the method’s detection limit;
• the blood-count abnormality is reactive rather than clonal;
• the person has a “triple-negative” MPN defined by morphology and other evidence.

A negative driver panel is not the end of the evaluation when the clinical picture remains concerning. Broader molecular profiling, cytogenetics, BCR::ABL1 testing, repeat marrow review, or evaluation for inherited thrombocytosis may be appropriate. The next step depends on age, blood-count pattern, marrow findings, family history, and whether the result would change care.

Occasionally, low-level MPL variants are found in a person without a definite MPN. This requires caution. Small acquired blood-cell clones become more common with age, and technical artifacts can occur near an assay’s threshold. The laboratory’s quality metrics, repeat testing, blood-count trajectory, and marrow findings help determine significance. A low VAF should not automatically be labeled cancer.

MPL in Essential Thrombocythemia and Myelofibrosis

MPL driver mutations occur in a minority of ET and PMF cases. Published series vary, but roughly 3%–8% of ET and 5%–10% of PMF carry MPL mutations. JAK2 is more common, and CALR is also more frequent in ET and PMF. MPL mutations are not a typical driver of polycythemia vera, where a JAK2 mutation is expected in nearly all cases.

In essential thrombocythemia, the marrow usually shows proliferation of enlarged, mature-appearing megakaryocytes with limited fibrosis and without the full pattern of another myeloid neoplasm. The diagnosis also requires exclusion of chronic myeloid leukemia, polycythemia vera, PMF, myelodysplastic syndromes, and reactive thrombocytosis. An MPL mutation supports clonality but cannot correct a poorly matched marrow pattern.

In prefibrotic PMF, megakaryocytes have abnormal maturation and dense clustering, with increased marrow cellularity and granulocytic proliferation but little fibrosis. This distinction matters because prefibrotic PMF and ET can present with similar platelet counts yet have different risks over time. Expert pathology review can be important when morphology is borderline.

In overt PMF, marrow fibrosis is more advanced and may accompany anemia, enlarged spleen, constitutional symptoms, immature blood cells in circulation, elevated lactate dehydrogenase, or low platelets in later disease. Prognostic systems use age, symptoms, blood counts, blasts, cytogenetics, and selected mutations. MPL is one part of this assessment, not the entire prognosis.

Driver genotype may correlate with clinical patterns at a population level. MPL-mutated ET can carry a meaningful thrombosis risk, and some cohorts suggest differences in progression compared with CALR-mutated disease. These associations are not precise enough to predict an individual outcome from MPL status alone. Prior thrombosis, age, cardiovascular factors, leukocyte count, marrow category, and additional high-risk mutations often have greater immediate influence.

Treatment and Prognosis

An MPL result usually influences diagnosis and risk assessment more directly than it selects an MPL-specific drug. There is no standard therapy chosen solely because an ET or PMF carries MPL W515L or W515K. Treatment is based on the diagnosed disease, symptoms, thrombosis or bleeding risk, blood counts, age, comorbidities, spleen burden, molecular risk, and patient preferences.

For ET, management may include observation, low-dose aspirin when appropriate, and cytoreductive therapy for higher-risk patients. Hydroxyurea, pegylated interferon, or anagrelide may be considered according to the clinical situation. Very high platelet counts can cause acquired von Willebrand syndrome and bleeding, so aspirin is not automatically safe simply because platelets are elevated. The clinician may check von Willebrand activity before recommending antiplatelet treatment in extreme thrombocytosis.

For PMF, care may include symptom-directed treatment, transfusion support, agents for anemia, JAK inhibitors for spleen or constitutional symptoms, and allogeneic stem cell transplantation for selected patients with sufficiently high-risk disease. JAK inhibitors can work even when the driver is MPL rather than JAK2 because signaling converges on the JAK-STAT pathway. Response, however, cannot be predicted from MPL positivity alone.

The mutation may be tracked over time in research settings or selected clinical situations, but routine serial MPL VAF monitoring is not equivalent to standardized molecular MRD testing in diseases such as NPM1-mutated AML. Blood counts, symptoms, spleen examination, marrow findings when indicated, and broader molecular evolution usually guide follow-up.

A newly detected additional mutation can matter if the disease changes. Rising blasts, worsening cytopenias, rapidly enlarging spleen, increasing symptoms, or other signs of progression may prompt repeat marrow and genomic testing. Treatment should never be changed from a molecular report without integrating the clinical picture.

Limitations and Follow-Up

The main limitation is that “MPL test” can describe assays with very different coverage. A narrow test may detect only W515L and W515K. A sequencing panel may cover all coding exons but have lower sensitivity for tiny clones. The report’s methodology and detection limit therefore matter as much as the word negative.

Sample quality can affect results. Blood usually works well because the mutation is present in myeloid cells, but recent treatment, low circulating clone size, or an inadequate marrow aspirate can reduce sensitivity. A dry tap in fibrotic marrow may limit aspirate-based studies, although blood or core-biopsy material may provide alternatives.

Other limitations include:

• a positive somatic mutation does not identify the exact MPN without morphology and clinical criteria;
• a negative result does not exclude an MPN;
• VAF does not directly equal disease severity;
• rare germline MPL variants require a separate inherited-disorder evaluation;
• clonal hematopoiesis and low-level findings can complicate interpretation;
• therapies and classifications evolve, so an older report may need reinterpretation.

Follow-up commonly includes a hematology visit, review of iron studies and inflammatory causes, repeat complete blood counts, peripheral smear, JAK2/CALR status, BCR::ABL1 testing when appropriate, and bone marrow biopsy. If an MPN is diagnosed, the clinician documents thrombosis history, bleeding, cardiovascular risks, symptoms, spleen size, and baseline molecular or cytogenetic findings.

Seek prompt medical care for symptoms that could signal thrombosis or major bleeding, such as sudden chest pain, shortness of breath, one-sided weakness, difficulty speaking, a painful swollen leg, severe new abdominal pain, black stools, vomiting blood, or uncontrolled bleeding. These symptoms require clinical assessment regardless of the mutation result.

Questions to Ask

A molecular report becomes more useful when the patient knows which diagnostic question it was intended to answer. Consider asking:

• Was my test limited to common MPL variants or did it sequence the full relevant region?
• Were JAK2, CALR, and BCR::ABL1 also tested?
• Does my bone marrow favor ET, prefibrotic PMF, overt PMF, or another diagnosis?
• Is the reported variant pathogenic, likely pathogenic, or uncertain?
• What does the VAF mean in my sample, and will it be used as a baseline?
• Could iron deficiency, inflammation, recent surgery, or another reactive cause explain my platelet count?
• How does my age, thrombosis history, blood count, and additional mutation profile affect risk?
• Do I need aspirin, cytoreduction, a JAK inhibitor, or observation?
• Which symptoms should lead me to urgent care?
• Is there any reason to investigate a rare inherited thrombocytosis syndrome in my family?

Keep a copy of the complete pathology and molecular reports, not only a portal summary. The exact specimen, method, coverage, variant notation, VAF, and interpretation may become important if the diagnosis is reviewed later or testing is repeated at another center. For a new MPN diagnosis or an ambiguous marrow classification, review by a hematopathologist with MPN expertise can prevent treatment based on an incomplete label.

A practical way to review the complete workup

A useful review starts with the blood-count timeline rather than the mutation. Record when thrombocytosis first appeared, the highest and most recent platelet counts, and whether hemoglobin or white blood cells changed at the same time. Then compare iron studies, C-reactive protein or other inflammation markers, infection history, recent surgery, bleeding, cancer, and medications. Reactive thrombocytosis often improves as the underlying cause resolves; an MPN pattern tends to persist or evolve.

Next, place MPL beside the marrow report. ET typically shows enlarged mature megakaryocytes with loose clustering, while prefibrotic PMF shows denser atypical clusters, abnormal nuclear features, and increased granulocytic growth. Fibrosis grade, cellularity, and blast percentage should be explicit. When a report says only “consistent with MPN,” ask whether the pathologist can narrow the category and whether an expert second review would change management.

The molecular profile should then be checked for completeness. A negative MPL result has different weight if JAK2 V617F, JAK2 exon 12, CALR exon 9, and BCR::ABL1 were appropriately assessed. In established myelofibrosis, additional high-molecular-risk genes may refine prognosis. In a younger person with lifelong thrombocytosis and affected relatives, an inherited thrombocytosis panel may be more relevant than repeating broad somatic testing.

Finally, connect the diagnosis to an explicit monitoring plan. The team should define how often complete blood counts will be checked, what platelet or symptom changes should trigger contact, and when marrow or molecular testing would be repeated. Document the plan for pregnancy, surgery, prolonged travel, estrogen exposure, or other situations that can alter clotting risk. A mutation report is most useful when it leads to this structured clinical follow-through.

A follow-up plan should also address cardiovascular risk because smoking, high blood pressure, diabetes, and high cholesterol add to thrombotic risk. These factors do not cause the MPL mutation, but treating them can reduce preventable complications. Patients should tell every clinician about the MPN before surgery or a new medication, since antiplatelet and cytoreductive plans may need temporary adjustment.

Pregnancy requires joint hematology and maternal-fetal medicine care. Platelet counts can change during pregnancy, and prior thrombosis, pregnancy loss, and disease category influence aspirin, anticoagulation, or interferon decisions. Hydroxyurea and several other drugs are avoided in pregnancy. The mutation result stays the same, but the clinical risk plan changes.

An MPL allele fraction should not be treated as a stand-alone measure of disease severity. The percentage can be influenced by specimen type, blood-cell composition, treatment, and assay design. Clinicians interpret it with counts, marrow findings, symptoms, cytogenetics, and other mutations rather than using one number as a universal stage marker.

References

• Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management 2024 (Review)
• Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management 2023 (Review)
• Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification 2025 (Review)
• Molecular profiling in MPN: who should have it and why? 2024 (Review)
• Myeloproliferative Neoplasms Treatment (PDQ®) 2025 (Official Review)

Disclaimer

This article provides general education about MPL mutation testing and cannot diagnose an MPN or determine treatment for an individual. Blood counts, marrow pathology, symptoms, and the complete molecular report must be reviewed by a qualified hematology team. Seek urgent medical care for possible clotting or serious bleeding symptoms.